English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture

Petiot, E., Jacob, D., Lanthier, S., Lohr, V., Ansorge, S., & Kamen, A. A. (2011). Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnology, 11(84), 1-12. doi:10.1186/1472-6750-11-84.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-8E03-2 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-002C-8C32-7
Genre: Journal Article

Files

show Files
hide Files
:
573861_bmc_biotech_2011.pdf (Publisher version), 2MB
Name:
573861_bmc_biotech_2011.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Locators

show

Creators

show
hide
 Creators:
Petiot, E.1, Author
Jacob, D.1, Author
Lanthier, S.1, Author
Lohr, V.2, Author              
Ansorge, S.1, Author
Kamen, A. A.1, Author
Affiliations:
1Biotechnology Research Institute Montreal, Quebec, Canada École Polytechnique de Montréal, Campus de l’Université de Montréal, Montréal, Québec, Canada., ou_persistent22              
2Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society, ou_1738140              

Content

show
hide
Free keywords: -
 Abstract: Background Cell culture-based production of influenza vaccine remains an attractive alternative to eggbased production. Short response time and high production yields are the key success factors for the broader adoption of cell culture technology for industrial manufacturing of pandemic and seasonal influenza vaccines. Recently, HEK293SF cells have been successfully used to produce influenza viruses, achieving hemagglutinin (HA) and infectious viral particle (IVP)titers in the highest ranges reported to date. In the same study, it was suggested that beyond 4x 106 cells/mL, viral production was limited by a lack of nutrients or an accumulation of toxic products. Results To further improve viral titers at high cell densities, erfusion culture mode was evaluated. Productivities of both perfusion and batch culture modes were compared at an infection cell density of 6 x 106 cells/mL. The metabolism, including glycolysis, glutaminolysis and amino acids utilization as well as physiological indicators such as viability and apoptosis were extensively documented for the two modes of culture before and after viral infection to identify potential metabolic limitations. A 3L bioreactor with a perfusion rate of 0.5 vol/day allowed us to reach maximal titers of 3.3 x 1011 IVP/mL and 4.0 logHA units/mL, corresponding to a total production of 1.0 x 1015 IVP and 7.8 logHA units after 3 days postinfection. Overall, perfusion mode titers were higher by almost one order of magnitude over the batch culture mode of production. This improvement was associated with an activation of the cell metabolism as seen by a 1.5-fold and 4-fold higher consumption rates of glucose and glutamine respectively. A shift in the viral production kinetics was also observed leading to an accumulation of more viable cells with a higher specific production and causing an increase in the total volumetric production of infectious influenza particles. Conclusions These results confirm that the HEK293SF cell is an excellent substrate for high yield production of influenza virus. Furthermore, there is great potential in further improving the production yields through better control of the cell culture environment and viral production kinetics. Once accomplished, this cell line can be promoted as an industrial platform for costeffective manufacturing of outbreaks the influenza seasonal vaccine as well as for periods of peak demand during pandemics. © 2011 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. [accessed November 30th, 2011]

Details

show
hide
Language(s): eng - English
 Dates: 2011
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: eDoc: 573861
DOI: 10.1186/1472-6750-11-84
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: BMC Biotechnology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 11 (84) Sequence Number: - Start / End Page: 1 - 12 Identifier: ISSN: 1472-6750